SCHEDULE 13G/A: Invus Entities and Raymond Debbane Disclose 9.4% Passive Stake in Solid Biosciences
Beneficial Ownership Report
A group of investment entities led by Raymond Debbane has filed an amended Schedule 13G, reporting a combined passive beneficial ownership of 9.4% in Solid Biosciences Inc. as of December 31, 2024.
Summary
- Invus Public Equities, L.P. and its affiliated entities (Invus Public Equities Advisors, LLC, Invus Global Management, LLC, and Siren, L.L.C.) collectively reported beneficial ownership of 3,265,927 shares of Solid Biosciences Inc. common stock, representing 8.2% of the class.
- Avicenna Life Sci Master Fund LP and its affiliated entities (Avicenna Life Sci Master GP LLC and Ulys, L.L.C.) collectively reported beneficial ownership of 483,114 shares, representing 1.2% of the class.
- Mr. Raymond Debbane, through his control over Siren and Ulys, is deemed to beneficially own a total of 3,749,041 shares, which constitutes 9.4% of Solid Biosciences Inc.'s common stock.
- The ownership percentages are calculated based on 39,954,607 shares outstanding as of November 1, 2024, as reported in Solid Biosciences Inc.'s Quarterly Report on Form 10-Q filed on November 6, 2024.
- The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain operational or financial performance data for Solid Biosciences Inc. The investment is stated as passive, leading to a neutral assessment regarding the company's operational performance, though the presence of a significant investor can be seen as a slight positive signal.
Positives
- The disclosure of a significant beneficial ownership stake (9.4%) by institutional investors and a prominent individual like Raymond Debbane may signal confidence in Solid Biosciences Inc.
- The investment is stated as passive, indicating no immediate intent to influence or change control, which can provide stability regarding the company's current management and strategic direction.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The disclosure of a significant passive stake by institutional investors and Raymond Debbane may be viewed positively, potentially indicating investor confidence and stability in the shareholder base.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date of shares outstanding calculation (39,954,607 shares) as reported in Solid Biosciences Inc.'s Form 10-Q. |
| 2024-11-06 | Date Solid Biosciences Inc. filed its Quarterly Report on Form 10-Q, which reported the shares outstanding. |
| 2024-12-31 | Date of event which requires the filing of this statement (beneficial ownership snapshot date). |
| 2025-02-12 | Date the Schedule 13G/A Amendment No. 3 was signed and filed. |
Keywords
Solid Biosciences Inc., SBL, Invus Public Equities, Avicenna Life Sci Master Fund, Raymond Debbane, Schedule 13G, beneficial ownership, passive stake, institutional investment, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.